Holen Sie sich die Stockscreener-App
1.86
4.49%
0.08
Alector Inc Aktie (ALEC) Neueste Nachrichten
Alector, Inc. (NASDAQ:ALEC) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Alector stock hits 52-week low at $1.73 amid market challenges - Investing.com Australia
Alector (NASDAQ:ALEC) Rating Lowered to “Neutral” at Mizuho - Defense World
BNP Paribas Financial Markets Cuts Stock Holdings in Alector, Inc. (NASDAQ:ALEC) - Defense World
Alector (NASDAQ:ALEC) Stock Rating Lowered by Mizuho - MarketBeat
Alector stock under pressure as key AL002 program removed—Mizuho - Investing.com
Alector stock under pressure as key AL002 program removed—Mizuho By Investing.com - Investing.com UK
Alector Inc. stock downgraded to Hold by Stifel, amid mixed biotechnology outlook - Investing.com Australia
Alector (NASDAQ:ALEC) Rating Lowered to "Hold" at Stifel Nicolaus - MarketBeat
Stifel Downgrades Alector (ALEC) - MSN
Verition Fund Management LLC Sells 473,794 Shares of Alector, Inc. (NASDAQ:ALEC) - MarketBeat
Alector stock hits 52-week low at $1.99 amid market challenges - Investing.com Australia
Short Interest in Alector, Inc. (NASDAQ:ALEC) Grows By 34.1% - MarketBeat
Alector, Inc. (NASDAQ:ALEC) Sees Large Growth in Short Interest - Defense World
Alector (ALEC) Stock Dips Amid Biotech Sector Volatility - GuruFocus.com
Point72 Asset Management L.P. Sells 529,847 Shares of Alector, Inc. (NASDAQ:ALEC) - MarketBeat
RA Capital Management, L.P. Acquires Significant Stake in Alecto - GuruFocus.com
Bank of America Downgrades Alector (NASDAQ:ALEC) to Underperform - Defense World
Alector downgraded to Underperform at BofA after Alzheimer's trial miss - MSN
Alector stock hits 52-week low at $2.36 amid market challenges - Investing.com Canada
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts - Benzinga
Alector (NASDAQ:ALEC) Downgraded to Underperform Rating by Bank of America - MarketBeat
Alector CFO Marc Grasso sells $41,542 in stock By Investing.com - Investing.com Canada
Alector's chief medical officer sells shares worth $37,518 By Investing.com - Investing.com Canada
Alector's chief medical officer sells shares worth $37,518 - Investing.com
Alector president and head of R&D sells $66,764 in stock - Investing.com
Alector president and head of R&D sells $66,764 in stock By Investing.com - Investing.com Canada
Alector CEO Rosenthal sells over $131,000 in stock - Investing.com
Alector CFO Marc Grasso sells $41,542 in stock - Investing.com
Alector CEO Rosenthal sells over $131,000 in stock By Investing.com - Investing.com UK
Deutsche Bank Initiates Coverage of Alector (ALEC) with Buy Recommendation - MSN
Vigil Neuroscience: Down On A Competitor's Failure (NASDAQ:VIGL) - Seeking Alpha
Alector (ALEC) Stock Drops 5.02% Amidst Market Volatility - GuruFocus.com
HC Wainwright Issues Pessimistic Forecast for Alector (NASDAQ:ALEC) Stock Price - Defense World
Braidwell LP Has $10.06 Million Stock Position in Alector, Inc. (NASDAQ:ALEC) - MarketBeat
HC Wainwright Cuts Alector (NASDAQ:ALEC) Price Target to $7.00 - MarketBeat
Q1 Earnings Estimate for Alector Issued By HC Wainwright - MarketBeat
Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates - Simply Wall St
Victory Capital Management Inc. Increases Position in Alector, Inc. (NASDAQ:ALEC) - Defense World
Alector (NASDAQ:ALEC) Stock Rating Lowered by Morgan Stanley - Defense World
Alector shares price target cut, retains buy amid clinical trial setback - Investing.com Australia
Alector: Bleak Prospects After Alzheimer's Failure (NASDAQ:ALEC) - Seeking Alpha
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance
Alector price target lowered to $7 from $35 at H.C. Wainwright - Yahoo Finance
Alector AL002 INVOKE-2 Phase II Alzheimer’s trial misses goal - The Pharma Letter
Alector (NASDAQ:ALEC) Given New $5.00 Price Target at BTIG Research - Defense World
Alector stock hits 52-week low at $2.61 amid market challenges - Investing.com Canada
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):